Ground Floor Opportunities in Biotechnology from The KonLin Letter

For more information about The KonLin Letter, visit the website at: www.konlin.com ?  Konrad Kuhn was recently featured by Select Information Exchange for his expertise in low-price, value-oriented stocks. He now sees enormous investor profit opportunities from a key biotech buyout forecast in this special report. One of America's Top Investment Advisors is steering his readers toward potential biotech buyouts. This is one of his favorites. "I'm forecasting 10x to 20x profit potential from this biotech innovator." 135 million Americans stand to benefit from its recent breakthroughs, which include a simple genetics test to identify specific cancer risks for an individual patient. Its second genetics test identifies an individual patient's drug risks, which could slash the annual $60 billion bill we pay for medical litigation, help drug makers meet new FDA guidelines, plus improve patient outcomes from a prescription drug. Since they beat everyone to the patent office with these breakthroughs, company founders are preparing for buyout from a major pharmaceutical company...their second since 2002! I'm advising my readers to pile onto this one...and you should too!

The Human Genome Project completed mapping the human DNA sequence in 2003. Now the race is on to see who can make that knowledge useful. 2006 should be a pivotal year for investing in the breakthrough science it creates. Forecast: ??” I anticipate that major pharmaceutical companies, such as Merck, Pfizer, et. al. will soon be bidding billions of dollars to acquire breakthrough technology, with the largest premiums being paid for innovations in genetics. Opportunity: ??” You could make a fortune by spotting and investing a company that is on the drug makers' radar screens right now. I recommend you move aggressively on Upstream Biosciences (UPBS). The founders previously sold their first genetics company to Merck in 2002 and now I'm predicting... Upstream Biosciences (UPBS) has all the signs of being an early buyout target... 1. Their unique genetics test that predicts a patient's risk for certain cancers. This test could begin benefiting 325 million adult Americans as early as next year! The test is already developed for liver cancer. Soon to follow: tests for prostate and colon cancer. 2. Their genetic drug response test that predicts a patient's risk for taking a drug. This test alone could slash drug makers' annual liability exposure of $60 to $110 billion! Further driving the need, new FDA guidelines make such tests inevitable for future drug development. ?  Investor profits from a UPBS acquisition should be enormous. You do not want to miss the big gains from an astute early buy! I'm telling my readers: Anticipate 1,000% to 2,000% growth potential from UPBS as big pharmaceuticals scramble to buy new technology and secure "must-have" competitive advantage. Dear Aggressive Investor, ??” I do not routinely make predictions like this, but due to recent advances in gene science, key areas in biotech are set to go ballistic. This creates one of the best wealth-building situations you'll see this decade. ??” Over the next few years, breakthroughs in genetics will radically alter the American health care system. Enormous sums will flow into genetics-based innovation. ??” Investors in the right companies today could grow rich from the gains that flow in this change. A multi-billion market in the making! ??” Just two years ago, International Data Corporation (IDC), one of the world's most respected industry trend analysts, glowingly projected this industry to debut as a $38 billion market in 2006. ??” That figure proved too aggressive, but the fault is only in the timing. By the end of the decade, revenues from genetics are universally acknowledged to become a multi-billion-dollar global market. ??” Experts in all fields of health care foresee genetic sciences as becoming essential in the development of new medications, treatments, and prediction of disease. ??” Investors do not want to miss the ground floor opportunities this creates. ??” Since I closely follow the biotech sector through The KonLin Letter, I've been diligently searching for innovators that could lead these changes...and become buyout targets for the big companies that have the resources to buy that innovation. Upstream Biosciences (UPBS) founders have a record for genetics science and business leadership. ??” Companies such as Upstream Biosciences are sure to be on pharmaceutical radar screens right now... ??” ...and its stock should be in your portfolio today! UPBS could become one of the hottest buy-out prospects in its sector. ??” Genetics pioneers like Upstream Biosciences are set to be worth a fortune as important early patents prove indispensable to drug-making in the future. Companies could bid fortunes to have them. ??” But innovations are not the sole reasons that Upstream Biosciences made the top of my list. ??” Company founders Bellenson and Smith already have experience at being an acquisition target. ??” They started their first genetics company in 1991. By the end of the decade, their first company, Pangea Systems (later renamed DoubleTwist), was ranked one of the top genetics companies in the world. It was listed on Red Herring's 'The Top 50 Companies" two years running. In 2002, the company was privately acquired by Merck. ??” Since that acquisition, Bellenson and Smith parlayed their experience to the next level in applied genetics, founding Upstream Biosciences and taking it public this year. They beat everyone to the patent office with two important genetics tests. ??” The company now owns two novel genetics tests that have enormous potential for health care. As reported above, one test predicts cancer risk and the other predicts a patient's outcome to a drug therapy. ??” Upstream Bioscience beat been everyone to the patent office with these tests and not surprisingly, the revenue potential from each is staggering to predict. ??” The cancer-specific tests alone could be in doctor's offices within 18 months, offering life-saving benefit to over 325 million Americans. ??” For investors, projecting millions in revenue from such tests is a no-brainer. ??” But the potential for Upstream Bioscience's pharmacogenomics test could be measured in billions of dollars and... ...that could make UPBS the closest you'll get to a slam dunk with any emerging biotechnology investment. ??” This test predicts an individual patient's likely response to any specific drug. It gives drug makers and physicians a tool if a drug will have a positive outcome or lead to adverse reactions...on a patient-by-patient basis. ??” Besides the incredible therapeutic advantages such a test offers physicians for treating disease and prescribing treatment, billions could be saved and The Bush administration reports that $60 to $110 billion is lost each year in drug litigation expense! Tests like Upstream Bioscience's could save the American health care system billions of dollars each year! ??” Had a test such as Upstream's been available in 2002, Merck might have avoided the $50 billion loss it could absorb for legal expenses in its Vioxx recall alone. ??” Multiply that by the hundreds of other drugs and the economic magnitude of this test becomes obvious. ??” For years now, respected institutions such as the American Medical Association (AMA) have predicted and prepared for the day when pharmacogenomics tests such as Upstream's become widely available. ??” In a few years, genetics tests could be as commonplace as blood tests. That means... ??” Upstream Biosciences could have the right product at the right time...ready to go! ??” Those familiar with my investment style know that I am aggressive in my outlook and conservative in my valuations. I specialize in finding low-price stocks poised on the edge of a major upside breakout. ??” For investors who want to get in early, UPBS is an aggressive buy with enormous potential that must be acted on right now. ??” With the publicity and news that is flowing daily in the biotech sector, I do not anticipate that UPBS will remain at current price levels for long. ??” Ever since the tech crash of 2000, biotech has been out-of-favor on Wall Street, but that will change rapidly in the coming months. ??” When genetics hits Main Street with products such as this, Wall Street is sure to follow. ??” Expect incredible buy pressure on stocks like UPBS, sending share prices soaring! ??” Newsweek Magazine just published a cover story on the mainstreaming of genetics testing. Once this kind of information makes it to the supermarket's magazine rack, investors will be quick to follow. ??” It's also been a topic that has been commonplace in medical journals for years. In 2001, the American Medical Association reported that gene testing will lead to the '...individualization of drug therapies based on genetic information, an application known as pharmacogenomics." 'Our findings serve as a foundation for further research on how pharmacogenomics can reduce the incidence of adverse reactions and on the resulting clinical, societal, and economic implications." ??” Upstream Biosciences submitted patents for novel gene-based cancer and drug tests that could prove essential in the evolution of pharmacogenomics and personalized medicine. In the coming years, such patents could be worth a fortune as licensed intellectual properties. ??” I foresee a feeding frenzy of biotech buyouts that will rock the pharmaceutical industry and create fabulous wealth-making potential from pioneering companies like UPBS. ??” With that in mind, I recommend the following: 1. Put UPBS on your buy list immediately. This ground floor opportunity will not last long. I forecast that biotechs will go ballistic this year and UPBS is one of my top picks for aggressive investing in this sector. 2. Prepare now for a tumultuous 2006 as investors confront the inevitable consequences of mismanaged monetary policies. I have been writing about this for some time now and all my signals tell me the piper is coming for his due now. Will you be prepared? The answers can be found in The KonLin Letter. 3. Subscribe today to The KonLin Letter to follow my picks, buy/sell recommendations, and economic forecasts. I've predicted every major economic event over the last two decades and my readers have been prepared in advance for the outcomes. That's an advantage you need now because this year will be one of the most challenging of all times! ??” To learn more about The KonLin Letter, visit the website at: www.konlin.com. Konrad Kuhn, Publisher The KonLin Letter ??” P.S. As forecast above, UPBS has 10x to 20x growth potential for those who get in now. ??” But, what may stun you to learn is that low-priced value-oriented stocks have historically proven to deliver 32x more growth than the S&P 500! The KonLin Letter was among the first to report this information to investors. ??” If you are an investor seeking to maximize your returns, then you DO NOT want to overlook this important fact. History has already proven the stunning wealth that accumulates in the low-price stock arena. ??” Here's how low-priced, value-oriented stocks could impact your portfolio. Comparing the historic performance of this stock category with large-caps, market data show that since July 1927, a $1,000 investment would achieve these end values: ?  79-year LARGE-CAP Portfolio End Value: $2.64 million 79-year SMALL-CAP Portfolio End Value: $84.48 million ??” To learn more about the implications of this report, visit The KonLin Letter website at: www.konlin.com. DISCLAIMER: This publicly distributed report of The KonLin Letter (TKL) is a sponsored advertisement. The distribution costs of this report to new subscribers, four hundred thousand dollars, were funded by Novar Capital Corporation in an effort to create investor awareness of Upstream Biosciences, Inc. and also to generate subscription revenue for TKL. Neither TKL nor Konrad Kuhn, the reviewer [or analyst], received any compensation for this report, but both expect to receive an unknown amount of revenue from new subscriptions from the subscription offer contained herein. Neither TKL nor Konrad Kuhn is an investment adviser or broker-dealer. Novar Capital Corporation owns 1.5 million shares of UPBS stock, 500,000 of which can be sold at anytime. This report, including the opinions expressed and the statements made within, are for informational and advertising purposes only and should not be construed as investment advice and do not constitute an offer to sell any securities, and it is not soliciting an offer to buy any securities in any state or other jurisdiction where the offer or sale is not permitted. The information used to prepare this report is believed to be from reliable sources, but no representation is made as to the accuracy or completeness of such information. Investment in securities carries a high degree of risk and involves risks and uncertainties that may result in investors losing all of their invested capital. The information contained herein contains 'forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are based upon expectations, estimates and projections at the time the statements are made and involve risks and uncertainties that could cause actual events to differ materially from those anticipated. Forward-looking statements may be identified through the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should, or might occur. Any statements that express or involve predictions, expectations, beliefs, plans, projections, objectives, goals or future events or performance may be forward-looking statements. Factors that could cause actual results to differ materially include but are not limited to adverse economic conditions, intense competition, lack of meaningful research results, inadequate capital, termination of contracts or agreements, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, and other risks detailed in the company's reports filed with the Securities and Exchange Commission. Readers should consult with their own professional investment, tax and portfolio advisors before making any investment decision and should independently verify all information herein. More complete information about Upstream Biosciences, Inc. is available from the website of the Securities and Exchange Commission, at http://www.sec.gov, and copies of its filings may be read without charge at and copied obtained at prescribed rates from the public reference facilities of the Commission, at 450 Fifth Street, NW, Washington, DC 20549.

86804/126878_logo150pxls.gif iosciences" src="http://i29.photobucket.com/albums/c268/danbreck/Upstream_email/logo150pxls.gif" width="160" border="0" name="Cont_17" livesrc="http://i29.photobucket.com/albums/c268/danbreck/Upstream_email/logo150pxls.gif" /> Company: Upstream Biosciences Symbol: OTC BB: UPBS Recommendation: Immediate Buy Now! Objective: Aggressive profit-making from an emerging new market sector. Strategy: Speculative buy and hold. Expect price volatility and rapid swings in short periods. Prepare to sell on news, buyout, or my sell signal in The KonLin Letter. Upside: 10x to 20x potential long-term profits Risk Factor: High In good faith, I cannot make this recommendation without a strong word of caution: This is a high risk investment not made for safe placement of your funds. I strongly advise that you limit your investment in UPBS to the amount you feel comfortable putting at high risk for loss. Company Website: www.upstreambio.com ?  - Konrad Kuhn, publisher of The KonLin Letter, is a leading expert picking small-caps with significant profit-making potential. "Think Small...Profit Big!" Mr. Kuhn is among the first to report the enormous profit-making advantage of investing in low-price small-cap stocks. This category has accumulated a massive 32 times greater rate of return than the S&P 500! You can learn more about this category of stocks as well as Konrad Kuhn's picks and forecasts by visiting The KonLin Letter website: www.konlin.com ?  - < 86804/126876_JoelDexsterDSC_0556COMBO.gif src="http://i29.photobucket.com/albums/c268/danbreck/Upstream_email/JoelDexsterDSC_0556COMBO.gif" width="150" border="1" name="Cont_19" livesrc="http://i29.photobucket.com/albums/c268/danbreck/Upstream_email/JoelDexsterDSC_0556COMBO.gif" /> These Stanford University graduates and founders of Upstream Biosciences, Joel Bellenson and Dexster Smith, have earned worldwide fame for their work in genetics and information management, the disciplinary foundations in the evolving field of applied pharmacogenomics. ?  They gained international fame as founders of Double Twist, one of the top 86804/126874_MerckWall150pxls.gif t="Merck" src="http://i29.photobucket.com/albums/c268/danbreck/Upstream_email/MerckWall150pxls.gif" width="150" border="1" name="Cont_20" livesrc="http://i29.photobucket.com/albums/c268/danbreck/Upstream_email/MerckWall150pxls.jpg" /> Bought out by Merck in 2002 ?  - - Bellenson and Smith made the cover of Wi 86804/126877_WiredCover112pxls.gif Magazine" src="http://i29.photobucket.com/albums/c268/danbreck/Upstream_email/WiredCover112pxls.gif" width="81" border="0" name="Cont_21" livesrc="http://i29.photobucket.com/albums/c268/danbreck/Upstream_email/WiredCover112pxls.jpg" /> Upstream's founders have been featured in Fortune Small Business, CNN/Money, Wall Street Journal, ABC Nightly News, Forbes and many other well-known international publications. Their first biotech company also made Red Herring's 'The Top 50 Companies" two years running. - - - < 86804/126870_logo2.gif Upstream Biosciences" src="http://i29.photobucket.com/albums/c268/danbreck/Upstream_email/logo2.gif" width="147" border="0" name="Cont_22" livesrc="http://i29.photobucket.com/albums/c268/danbreck/Upstream_email/logo.gif" /> If UPBS is the kind of stock that you like to have in your portfolio, then visit The KonLin Letter website at www.konlin.com - Kristen Silverberg, Deputy Assistant to the President for Domestic Policy, reports that Americans now spend 'between $60 to $110 billion a year in higher health care costs" due to medical litigation. Pharmacogenomics tests could put an end to many of these suits. - Young genetic pioneers are using the genome map to open rapidly growing frontiers in medicine... and the leaders will lay claim to the most fertile intellectual properties. Beginning with research budgeted in 1988, efforts to map and understand the human genome unfolded to become one of the most important arenas of pure research in history. By the year 2000, a few promising commercial ventures in genetic bioinformatics had been born. However, lacking immediate revenue potential, the best technologies (like DoubleTwist's) were scooped up by major corporations such as IBM, Roche and Merck at bargain prices during the 2000 to 2002 technology market crash. By 2003, the work of the human genome project had been completed. The enormous significance of this accomplishment (probably greater than putting a man on the moon in terms of effect on humanity) has triggered the first sparks of revolutionary change in medicine. Among the industry pioneers during this time was the company DoubleTwist, founded by Upstream's Joel Bellenson and Dexter Smith. DoubleTwist became one of 86804/126881_doubletwistWindow.gif ght="113" src="http://i29.photobucket.com/albums/c268/danbreck/Upstream_email/doubletwistWindow.gif" width="150" border="1" name="Cont_25" livesrc="http://i29.photobucket.com/albums/c268/danbreck/Upstream_email/doubletwist.jpg" /> By 2002, the Upstream team had assembled one of the world's most complete genome databases. DoubleTwist Debuts Online Service By BIO-IT World 03/07/02-DoubleTwist, Inc. is offering a new online information service, GenomeZone, which provides access to the DoubleTwist Annotated Human Genome Database. The new offering consolidates information from 35 public and private sources, and includes DoubleTwist's proprietary human and mouse gene indices. '...big pharmaceutical companies buy everything. They've got the resources, and they don't want to get caught missing something," says Michael Swenson, life sciences analyst at International Data Corp. - - Company: Upstream Biosciences Symbol: OTC BB: UPBS Recommendation: Immediate Buy Now! Objective: Aggressive profit-making from an emerging new market sector. Strategy: Speculative buy and hold. Expect price volatility and rapid swings in short periods. Prepare to sell on news, buyout, or my sell signal in The KonLin Letter. Upside: 10x to 20x potential long-term profits Risk Factor: High In good faith, I cannot make this recommendation without a strong word of caution: This is a high risk investment not made for safe placement of your funds. I strongly advise that you limit your investment in UPBS to the amount you feel comfortable putting at high risk for loss. Company Website: www.upstreambio.com - -< 86804/126883_KonradKuhn_CUhead2.gif ad Kuhn" src="http://i29.photobucket.com/albums/c268/danbreck/Upstream_email/KonradKuhn_CUhead2.gif" width="101" border="1" name="Cont_27" livesrc="http://i29.photobucket.com/albums/c268/danbreck/Upstream_email/KonradKuhn_CUhead.gif" /> Konrad Kuhn, publisher of the KonLin Letter, is a leading expert picking small-caps with significant profit-making potential. For more information about a subscription to The KonLin Letter, visit the website at www.konlin.com

Disclaimer This profile published by OTC Live, Inc is an independent electronic publication providing information and factual analysis on selected companies. All statements and expressions are the opinion of OTC Live, Inc and are not meant to be either investment advice or a solicitation or recommendation to buy, sell, or hold securities. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. OTC Live, Inc is not a broker dealer or a registered investment advisor . It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Profiles rely on information provided by the featured Companies and/or Edgar filings. While OTC Live, Inc believes its sources to be reliable, associates of OTC Live, Inc, or any affiliated parties make no representation or warranty as to the accuracy of the information provided. Readers should not rely solely on the information contained in this publication, but should consult with their own independent tax, business and financial advisors with respect to any investment opportunity, including any contemplated investment in the advertised Company. Factual statements in this publication are made as of the date stated and are subject to change without notice. OTC Live, Inc is not responsible for any claims made by the Company. We have prepared this report, drawing upon a range of public news, the company's website and information from sources in the industry, as well as data and opinions provided by the company. Prior to issuing this report, the Company reviewed and approved the contents in writing hereof. OTC Live, Inc has not independently verified the Company's representations. Any opinions expressed in this report are statements of judgment as of the date of publication. We urge readers to carefully verify all presentations within the report independently. The receipt of this publication shall not create, under any circumstances, any implication that there has been no change in the affairs of the company profiled since the date of review. This advertisement does not provide an analysis of the Company's financial position. OTC Live, Inc of this advertisement has been compensated eight thousand dollars by a third party for the preparation and electronic dissemination of this report. This should be viewed as a potential conflict of interest. Furthermore, associates of OTC Live, Inc may have stock positions on profiled companies from time to time. We may profit in the event the shares of the Company profiled by us increase in value. These positions may be liquidated from time to time even after we have made positive comments regarding the Company. The receipt of this information constitutes your acceptance of these terms and conditions. SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS: Except for historical information contained herein, the statements on this website and newsletter are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results in the future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product price volatility, product demand, market competition and risk inherent in the companies operations. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ``anticipate,'' ``estimate,'' ``expect,'' ``project,'' ``intend,'' ``plan,", "anticipate", "guess", "think", "hear", "suggest", ``believe,'' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. As a suggestion, "Never, ever, make an investment based solely on what you read in an online newsletter or Internet bulletin board, especially if the investment involves a small, thinly-traded company that isn't well known," said Nancy M. Smith, Director of SEC's Office of Investor Education and Assistance. "Assume that the information about these companies is not trustworthy unless you can prove otherwise through your own independent research." "Internet Fraud" is available on the SEC's Web Site, at http://www.sec.gov/consumer/cyberfr.htm.